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X-linked lymphoproliferative disease (XLP) is a pri-
mary immunodeficiency characterized by extreme sus-
ceptibility to Epstein-Barr virus. The XLP disease gene
product SH2D1A (SAP) interacts via its SH2 domain with
a motif (TIYXXV) present in the cytoplasmic tail of the
cell-surface receptors CD150/SLAM, CD84, CD229/Ly-9,
and CD244/2B4. Characteristically, the SH2D1A three-
pronged interaction with Tyr281 of CD150 can occur in
absence of phosphorylation. Here we analyze the effect of
SH2D1A protein missense mutations identified in 10 XLP
families. Two sets of mutants were found: (i) mutants with
a marked decreased protein half-life (e.g. Y7C, S28R,
Q99P, P101L, V102G, and X129R) and (ii) mutants with
structural changes that differently affect the interaction
with the four receptors. In the second group, mutations
that disrupt the interaction between the SH2D1A hydro-
phobic cleft and Val3 of its binding motif (e.g. T68I) and
mutations that interfere with the SH2D1A phosphoty-
rosine-binding pocket (e.g. C42W) abrogated SH2D1A
binding to all four receptors. Surprisingly, a mutation in
SH2D1A able to interfere with Thr 2 of the CD150 bind-
ing motif (mutant T53I) severely impaired non-phospho-
tyrosine interactions while preserving unaffected the
binding of SH2D1A to phosphorylated CD150. Mutant
T53I, however, did not bind to CD229 and CD224, suggest-
ing that SH2D1A controls several critical signaling path-
ways in T and natural killer cells. Because no correlation
is present between identified types of mutations and XLP
patient clinical presentation, additional unidentified ge-
netic or environmental factors must play a strong role in
XLP disease manifestations.
X-linked lymphoproliferative (XLP)1 disease is an immune
disorder characterized by an extreme vulnerability to Epstein-
Barr virus (EBV) (1–7). Fatal infectious mononucleosis, dys-
gammaglobulinemia, and malignant lymphoma are the major
XLP phenotypes (1). Although XLP patients can develop dys-
gammaglobulinemia and B cell lymphomas after an EBV infec-
tion, a causal relationship between the virus and these XLP
phenotypes has not been established. Indeed, immunoglobulin
deficiencies and B cell non-Hodgkin’s lymphomas have now
been observed in XLP patients who were sero- and/or polymer-
ase chain reaction-negative for EBV (8–10). Patients infected
with EBV mount an uncontrolled polyclonal expansion of T and
B cells that leads to death through hepatic necrosis and bone
marrow failure (1). NK cell dysfunctions are detected in some
(but not all) XLP patients (11–14).
The XLP gene encodes a 128-residue protein (SAP or
SH2D1A), which comprises an SH2 domain and a C-terminal
26-amino acid tail (15–17). The SH2D1A SH2 domain, ex-
pressed in the cytoplasm of T, NK, and possibly B cells (18),
binds to a consensus motif in the cytoplasmic tail of CD150
(16), CD244 (11, 13, 19, 20), and CD229 and CD84 (21, 22).
These glycoproteins are members of the CD150 family (5, 23)
and are expressed on a variety of hematopoietic cells. CD150 is
found on CD45ROhigh memory T cells, immature thymocytes, a
small fraction of B cells, and activated dendritic cells and is
rapidly up-regulated upon activation of T, B, and dendritic cells
(24). Anti-CD150 antibodies are also particularly effective in
inducing interferon- by both Th1 clones and mitogen-acti-
vated human or mouse T lymphocytes (25, 26). Importantly,
SH2D1A has been shown to block recruitment of the SHP-2
phosphatase to the tail of phosphorylated CD150 (16). As
CD150 is a self-ligand, it is thought to be involved in T/B cell
interactions and is therefore relevant to a model for pathogen-
esis of XLP (5, 16, 24, 27). CD150 was also recently identified as
another receptor for the measles virus (28).
CD244 is an N-glycosylated protein predominantly ex-
pressed on NK cells,  T cells, monocytes, and a subset of
CD8 T cells (29). The high affinity between CD244 and its
ligand CD48 (30, 31) is of particular relevance to NK and CD8
T cell responses in XLP because CD48 is one of the major
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receptors up-regulated on B cells following EBV transforma-
tion. Moreover, a defect in NK cell-mediated cytotoxicity in
some XLP patients was attributed to dysfunctional signaling
by CD244 (11, 12, 14).
SH2D1A has recently been shown to interact with a 62-kDa
adapter, Dok1 (p62dok) (32). Dok1 is present in hematopoietic
cells, where Dok1 constitutively associates with the p120Ras
GTPase-activating protein (32).
Classically, high affinity association of SH2 domains with
Tyr-containing motifs (i) depends upon phosphorylation of the
Tyr in the ligand and (ii) requires that the Tyr(P) be embedded
within a specific amino acid sequence, where an additional
contact C-terminal (usually at position 3) to the Tyr(P) is
established. To bind to the non-phosphorylated CD150 Tyr281
motif, the SH2 domain of SH2D1A uses a “three-pronged”
modality of binding instead of a conventional “two-pronged”
recognition (16, 33, 34). The SH2D1A structure characteristi-
cally includes a central  sheet with  helices packed against
either side (33). The additional interactions of SH2D1A involve
the side chains of residues 2 and 1 (Thr279 and Ile280)
adjacent to Tyr281 in the CD150 peptide. These interact with
residues in the D strand of the SH2 domain (33). The
SH2D1A-binding motif TIpYXXV is also found in the cytoplas-
mic domains of CD229 and CD84 (35, 36).
Several classes of SH2D1A mutations have so far been iden-
tified in XLP patients: (a) micro/macrodeletions, (b) mutations
interfering with mRNA transcription or splicing, and (c) non-
sense mutations or amino acid substitutions. Because missense
mutations spanning the entire SH2D1A coding sequence have
been identified in XLP patients (9, 15, 16, 37), SH2D1A pro-
vides a unique model to study structure/function relationships
in an SH2 domain.
Here, we analyze a series of SH2D1A proteins with missense
mutations by in vitro and in vivo studies. We report differential
binding of these mutants to the hematopoietic cell receptors
CD150, CD244, CD229, and CD84. Two major classes of
SH2D1A missense mutations are identified depending on their
protein half-life. Particular attention was focused on the
SH2D1A T53I amino acid substitution because its ability to
bind to non-phosphorylated CD150 is affected, whereas it binds
normally to phosphorylated CD150. However, further studies
show that T53I does not bind to receptors CD229 and CD244.
The study emphasizes that SH2D1A controls multiple signal
transduction pathways relevant to the pathogenesis of XLP.
EXPERIMENTAL PROCEDURES
Cells and Antibodies—COS-7 cells were cultured as described (16).
The Jurkat T cell line was obtained from American Type Culture
Collection. Anti-human CD150 monoclonal antibody was a gift from
DNAX Research Institute (25). Anti-FLAG monoclonal antibody M5
(Eastman Kodak Co.) and rabbit anti-SHP-2 polyclonal antibody (Santa
Cruz Biotechnology) were used in Western blotting. Horseradish per-
oxidase-conjugated goat anti-mouse and anti-rabbit IgG polyclonal an-
tibodies were purchased from Santa Cruz Biotechnology. The anti-
phosphotyrosine antibody was purchased from Zymed Laboratories Inc.
The anti-mouse CD244 monoclonal antibody was purchased from
Pharmingen. Anti-human CD229 (clone HCD229.1.84) and CD84
(clones CD84.1.2.21 and CD84.1.7) antibodies were produced by immu-
nizing BALB/c mice with 300.19 murine cells stably transfected with
full-length cDNA.
Plasmid Construction and Transfection—Human SH2D1A cDNA
was cloned in vector pCMV-FLAG (Kodak) to generate a FLAG-
SH2D1A construct. cDNAs coding for SH2D1A mutants based on XLP
patient sequences were generated by site-directed mutagenesis in po-
lymerase chain reactions using oligonucleotide primers incorporating
the point mutation. Human WT SH2D1A and mutants R32Q, T53I, and
T68I coding regions were cloned in vector pGEX2T (Amersham Phar-
macia Biotech) to generate GST-SH2D1A constructs. The mouse CD244
coding region was cloned in vector pcDNA3.1. The human CD150 cDNA
in vector pJFE14-SR was a gift from DNAX Research Institute. Hu-
man CD229 and CD84 cDNAs were expressed by a pcDNA3.1 vector.
COS-7 cells (10  106) were transfected with different expression
vectors containing the appropriate cDNA insert by the DEAE-dextran
method (38) or using the LipofectAMINE method (Roche Molecular
Biochemicals). Cells were harvested 72 h after transfection.
For cloning of rhesus monkey (Macaca mulatta) and cotton-top tama-
rin (Saguinus oedipus) SH2D1A, total mRNA was extracted from pe-
ripheral blood lymphocytes using the Trizol extraction method (Life
Technologies, Inc.). Oligonucleotides based on the 5-untranslated (for-
ward, GCC TGG TGG ACT CTT GG) and 3-untranslated (reverse, GAA
CTG TAT TAT CTA CAA TAT ATA AGA C) regions of human SH2D1A
were generated and used to amplify monkey SH2D1A cDNA by reverse
transcription-polymerase chain reaction. Products were subcloned in a
TA cloning vector (TA cloning kit, Invitrogen) and sequenced.
Immunoprecipitation and Western Blotting—After lysis of the cells
with 0.5% CHAPS, immunoprecipitations were done using the indi-
cated antibodies and 30 l of protein G-agarose beads for 2 h at 4 °C.
Proteins were separated by SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membrane (Immobilon, Milli-
pore Corp.). Filters were blocked for 1 h with 5% skim milk (or 3%
bovine serum albumin) and then probed with the indicated antibodies.
Bound antibody was revealed using horseradish peroxidase-conjugated
secondary antibodies by enhanced chemiluminescence (Supersignal,
Pierce). For anti-phosphotyrosine blotting, we used a directly conju-
gated horseradish peroxidase/antibody mixture (Zymed Laboratories
Inc.).
Pulse-Chase Assay—Transfected COS-7 cells were starved for methi-
onine and cysteine for 1 h and then pulse-labeled for 3 h with [35S]me-
thionine and [35S]cysteine using Tran35S-label (ICN Radiochemicals,
Cleveland, OH) (39). Newly synthesized proteins were chased for vari-
ous times in complete medium containing cycloheximide (final concen-
tration of 25 g/ml). Cell aliquots (5  106 cells/lane) were lysed, and
the fate of radiolabeled SH2D1A was analyzed by immunoprecipitation
with the M5 antibody to FLAG. SDS-polyacrylamide gel electrophoresis
was performed using 15% density. Gels were fixed and incubated with
Amplify (Amersham Pharmacia Biotech) before autoradiography.
Fluorescence Polarization Binding Assay—Interactions between
GST-SH2D1A proteins and a synthetic fluorescent peptide of 11 amino
acids (KSLTIpYAQVQK) corresponding to residues 276–286 of human
CD150 were measured in a fluorescence polarimeter according to
Danliker et al. (40). Polarization values were determined in a Beacon
system and were expressed in millipolarization units. Before perform-
ing equilibrium binding experiments, the time to reach equilibrium was
determined. Under the conditions used, the time required was 2 min
(data not shown). Equilibrium binding isotherms were constructed by
titrating a fixed concentration of fluorescent peptide (below the proba-
ble kD) with increasing amounts of the GST-SH2D1A mutant chimeric
proteins. The same data were also used to construct a Klotz plot (mil-
lipolarization units versus log[GST-SH2D1A mutants]). The curves
were fit by nonlinear regression using Prism curve-fitting software
(GraphPAD Software, San Diego, CA).
RESULTS
Single Amino Acid Substitutions Affect the Stability of the
SH2D1A Protein—One XLP patient was found to carry a mu-
tation in the 3-splice acceptor of the second intron of SH2D1A,
determining an inefficiency in mRNA processing (16). Because
of this mutation, only 5–10% of WT mRNA was present in the
patient’s T cells, whereas most of the SH2D1A mRNA did not
contain exon 2 (16). This prompted us to investigate whether
missense mutations can affect the stability of the SH2D1A
protein and thus the SH2D1A level in the cell, leading to a
disease phenotype. To test this hypothesis, the protein half-
lives of 10 mutant SH2D1A proteins (Y7C (A2), S28R (B1),
R32T (B5), C42W (C4), T53I (D4), T68I (E6), Q99P, P101L
(G2), V102G (G3), and Stop128R (tail)) (Fig. 1) were deter-
mined. The location of each mutation in the three-dimensional
structure of the protein (33) is indicated in parentheses. These
mutations exclusively correspond to amino acid residues that
are highly conserved in human, rhesus monkey (GenBankTM/
EBI accession number AF322912), cotton-top tamarin (acces-
sion number AF322913), and mouse SH2D1A genes (Fig. 1).
Specifically, COS-7 cells were transiently transfected with
SH2D1A cDNAs (WT or mutant) in a FLAG-tagged vector and
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metabolically labeled with [35S]methionine and [35S]cysteine
for 3 h. The cells were then incubated in medium containing
cycloheximide and nonradioactive amino acids for the indicated
time intervals (0, 3, 6, 10, and 20 h) (Fig. 2a). The half-life of the
WT SH2D1A protein was also measured in the Jurkat T cell
line (Fig. 2b). Jurkat cells were labeled under the same condi-
tions, and the endogenous SH2D1A protein was immunopre-
cipitated. Fig. 2b shows that the half-life of T cell endogenous
SH2D1A is comparable to that measured in the COS-7 cell
assay (Fig. 2a).
When FLAG-tagged proteins were immunoprecipitated and
analyzed by SDS-polyacrylamide gel electrophoresis (Fig. 2a), a
number of missense mutations were found to dramatically
shorten the half-life of SH2D1A. This was readily detectable
because the WT SH2D1A protein was stable with an apparent
half-life of 18 h (Fig. 2a, first panel). The half-lives of three
mutant SH2D1A proteins (C42W, T53I, and T68I) were unaf-
fected by the mutation, whereas the majority of the amino acid
substitutions resulted in an extremely shortened protein half-
life (Fig. 2a). Inspection of the SH2D1A three-dimensional
structure (33) indicated that most of the amino acid substitu-
tions that affect protein half-life localized to the backbone of
the SH2D1A SH2 domain. Surprisingly, the Stop129R mutant,
the only point mutation outside of the SH2 domain, also had a
drastically shortened half-life. Taken together, these observa-
tions support the notion that SH2D1A needs to be present in
the cell at an optimal level in order to function normally.
In Vivo Binding of Selected SH2D1A Mutants to CD150—
Previous experiments had shown that the tyrosine phospha-
tase SHP-2 binds to the cytoplasmic tail of human CD150 upon
phosphorylation of its tyrosines (16). Mutational analyses
showed that SHP-2 binds to phosphorylated tyrosines 281 and
327 of the cytoplasmic tail of CD150. The peptide segment
around Tyr327 also binds SH2D1A, but this interaction appears
to be more dependent upon phosphorylation of the tyrosine
than the Tyr281 site.2 To test whether mutant SH2D1A pro-
teins had lost their ability to block recruitment of the tyrosine
phosphatase SHP-2 to CD150, a COS-7 cell assay was used.
COS-7 cells were transiently transfected with combinations of
plasmids coding for SH2D1A (WT or mutant) and CD150. To
phosphorylate the tyrosines in the cytoplasmic tail of CD150, a
cDNA encoding the tyrosine kinase Fyn was cotransfected.
After 72 h, cells were lysed, and post-nuclear lysates were
immunoprecipitated with anti-CD150 antibodies. WT SH2D1A
bound to both phosphorylated and non-phosphorylated CD150
and, as expected, blocked SHP-2 recruitment to phosphorylated
CD150 completely (Fig. 3A, lanes 3 and 4). Almost all SH2D1A
mutants had lost their ability to block SHP-2 recruitment; as
expected, the proteins that had shortened half-lives belonged to
this group (data not shown).
Two mutants that disrupt the phosphotyrosine-binding
pocket of SH2D1A were analyzed. Mutant R32Q, which was
predicted to affect interactions with both the Tyr(P)281 and
Tyr281 peptides (33), was unable to bind the phosphorylated
and non-phosphorylated CD150 proteins (Fig. 3A, lanes 5 and
6). R32Q also completely failed to block SHP-2 recruitment.
Because mutant R32Q does not only have a mutation that
grossly disrupts binding to phosphorylated and non-phospho-
rylated CD150, as R32Q is present in reduced copies in the cell,
its lack of SHP-2 competition is likely to be the result of both
properties. By contrast, mutant C42W is a relatively stable
2 D. Howie and C. Terhorst, submitted for publication.
FIG. 1. Locations of missense mutations in the SH2D1A protein
sequence. The SH2D1A coding regions of different species and XLP
patient missense mutations analyzed in this work are reported. Mis-
sense mutations found in XLP patients are located in residues that are
fully conserved between human, rhesus monkey, cotton-top tamarin,
and mouse SH2D1A coding regions. hu, human; rh, rhesus monkey; ta,
cotton-top tamarin; mo, mouse. XLP patient amino acid substitutions
are indicated above the sequences (Y7C (A2), S28R (B1), R32T (B5),
C42W (C4), T53I (D4), T68I (E6), Q99P, P101L (G2), V102G (G3),
and Stop128R (tail)). Conserved amino acid positions in the human
homologous sequences are indicated by dashes. Residues that are lack-
ing in the cotton-top tamarin and mouse homolog sequences are indi-
cated with asterisks.
FIG. 2. Determination of mutant SH2D1A protein half-lives. a,
determination of mutant SH2D1A protein half-lives in COS-7 cells.
Mutant SH2D1A protein half-lives were determined as described under
“Experimental Procedures.” Each panel shows an autoradiograph of
[35S]methionine- and [35S]cysteine-labeled SH2D1A at different times
(0, 3, 6 10, and 20 h) after removal of the protein synthesis inhibitor
cycloheximide. Mutant designations are indicated to the left of each
panel. As evident, most of the mutant proteins presented extremely
shortened half-lives, whereas three of them (C42W, T53I, and T68I)
maintained stability comparable to that of the WT protein. b, determi-
nation of SH2D1A protein half-life in the Jurkat T cell line.
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protein (Fig. 2a), and its position in the SH2D1A structure
predicts that it could also interfere with binding to both phos-
phorylated and non-phosphorylated CD150. This is indeed the
case, as shown in Fig. 3B (lanes 7 and 8). This lack of binding
is therefore consistent with an important role for Cys42 in the
interactions with the CD150 tyrosine site.
A second stable mutant protein (T68I) did bind phosphoryl-
ated CD150, but not the non-phosphorylated CD150 protein
(Fig. 3A, lanes 7 and 8). However, its ability to block SHP-2
binding to phosphorylated CD150 was reduced. This mutation
affects the interaction of Val284 at position 3 of the CD150
peptide with the hydrophobic cleft of SH2D1A. Taken together,
the COS-7 in vivo protein binding experiments emphasized the
importance of SH2D1A protein stability in blocking recruit-
ment of SHP-2. Moreover, as predicted from the structure of
the SH2D1A SH2 domain, mutations that affect the tyrosine-
binding pocket or the hydrophobic cleft of SH2D1A reduce the
affinity of the mutant protein for both phosphorylated and
non-phosphorylated CD150.
One of the stable mutants of SH2D1A found in XLP patients
displayed an unexpected in vivo binding pattern. As shown in
Fig. 3B (lane 5), mutant T53I failed to bind to non-phosphoryl-
ated CD150 in COS-7 cells. However, its ability to bind CD150
after phosphorylation was preserved, and the T53I protein
excluded the tyrosine phosphatase SHP-2 from its docking site
in CD150 (Fig. 3B, lane 6). Because of this unique binding
pattern, T53I was studied further.
Mutation T53I in SH2D1A Selectively Disrupts Binding to
the Non-phosphorylated Form of the CD150 Tyr281 Peptide—
Binding of SH2D1A T53I to the CD150 Tyr281 and Tyr(P)281
peptides was compared with the binding of WT SH2D1A to the
same peptides by fluorescence polarization. For these experi-
ments, an 11-mer amino acid peptide encompassing CD150
cytoplasmic region 276–286 was labeled with fluorescein iso-
thiocyanate in its -amino group. This peptide, which repre-
sents the major SH2D1A-binding site in CD150, was used
previously for fluorescence polarization studies with WT
SH2D1A (34). Binding of this peptide to SH2D1A (either in the
presence or absence of CD150 Tyr281 phosphorylation) was
determined by incubating varying concentrations of GST-
SH2D1A with the peptides. As shown in Fig. 4a, SH2D1A T53I
bound to the phosphorylated peptide with an affinity compara-
ble to that of the WT protein (kD  0.25 M) (Fig. 4c). By
contrast, SH2D1A T53I bound the non-phosphorylated peptide
with a significantly decreased affinity (kD  8.7 M) (Fig. 4, b
and c).
In a parallel study, the SH2D1A T68I mutant protein was
also assayed for peptide binding using fluorescence polariza-
FIG. 3. Analysis of in vivo binding of SH2D1A mutants to the CD150 receptor. In vivo interactions were examined after cotransfection
of combinations of WT SH2D1A or mutant proteins R32Q, C42W, T53I, and/or T68I (in pCMV-FLAG) with human CD150 into COS-7 cells.
Combinations of cDNAs used in the transfections are indicated above panels a and b (, transfection of the indicated molecule;, transfection with
an equal amount of empty vector). A cDNA encoding human Fyn was cotransfected as indicated (). In the lanes 1 and 2 of each panel, an equal
amount of pCMV-FLAG empty vector (cmv) was used. I.P., immunoprecipitate; W.L., whole lysate. All cells were biotinylated prior to subjection
to detergent lysis. Cell lysates (1 107 cell eq) were subjected to immunoprecipitation with monoclonal antibody recognizing CD150. Samples were
analyzed by Western blotting (W.B.) with anti-phosphotyrosine antibody (-PY), horseradish peroxidase-conjugated avidin (AV-HRP), anti-FLAG
antibody, and anti-SHP-2 antibody, as indicated to the left of each panel. A, SH2D1A R32Q and T68I binding to CD150; B, SH2D1A C42W and
T53I binding to CD150.
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tion. T68I displayed a dramatically reduced affinity for the
phosphorylated peptide (kD  5.08 M) (Fig. 4, a and c),
whereas it failed completely to bind the non-phosphorylated
peptide (Fig. 4, b and c). Thus, mutant T68I is incapable of
binding to CD150 Tyr281 in both the phosphorylated and non-
phosphorylated states.
Structural Modeling of the SH2D1A T53I Mutant—High af-
finity association of SH2 domains with Tyr-containing motifs
depends upon phosphorylation of the Tyr embedded in the
ligand motif. The SH2 domain of SH2D1A represents the first
example of an SH2 domain able to bind a motif in the absence
of tyrosine phosphorylation. The three-pronged modality of
SH2D1A binding to CD150 was originally proposed as respon-
sible for its ability to block recruitment of SH2 domain-contain-
ing adapters and enzymes. Because our results indicate that
the SH2D1A T53I mutant selectively interferes with CD150
binding in the absence of Tyr281 phosphorylation, a structural
model for T53I was generated based on the structure of
SH2D1A (33). To this purpose, the structure of the SH2D1A
SH2 domain was altered by substituting Thr53 with isoleucine.
A model of the SH2D1A T53I mutant SH2 domain in complex
with the CD150 Tyr281 peptide is shown in Fig. 5. Replacement
of Thr53 with isoleucine eliminates the binding pocket for Thr
at position 2 (Thr279) of CD150. This prevents the interaction
of Thr at position 2 with a buried water molecule and with
Glu17, thus blocking interactions of one of the amino acids
located N-terminal to Tyr281. Thus, this selective amino acid
substitution changes the unique SH2 domain of SH2D1A into a
more conventional SH2 domain structure that predominantly
binds to a phosphorylated state of the ligand.
Binding to CD229, CD244, and CD84—In addition to
CD150, SH2D1A binds to at least three other transmembrane
glycoproteins of the CD150 family: CD244 (2B4) (19, 20),
CD229 (Ly-9), and CD84 (21). Therefore, mutants C42W, T53I,
and T68I were tested for their ability to bind to these receptors.
COS-7 cells were transiently transfected with combinations of
plasmids coding for SH2D1A (WT or mutant) and CD244 (Fig.
6, A and B), CD84 (Fig. 6C), or CD229 (Fig. 6D). Lanes 1 and 2
in Fig. 6 (A–D) are the negative controls (where a FLAG-tagged
empty vector was used), whereas in lanes 3 and 4, a FLAG-
tagged WT SH2D1A vector was used as a positive control.
Compared with WT SH2D1A, binding of SH2D1A mutants
C42W (Fig. 6A, lanes 5 and 6), T53I (Fig. 6A, lanes 7 and 8), and
T68I (Fig. 6B, lanes 5 and 6) to the CD244 receptor was totally
disrupted. Binding of these mutants to CD84 (Fig. 6C) and
CD229 (Fig. 6D) was also severely impaired, albeit that of
mutant T53I preserved a marginal binding to CD84 (Fig. 6C,
lanes 9 and 10). These results indicate that amino acid substi-
FIG. 4. In vitro binding of SH2D1A mutants T53I and T68I to a
CD150 peptide. Fluorescence polarization measurements of the inter-
action between scalar concentrations of GST-WT SH2D1A, GST-
SH2D1A T53I, or GST-SH2D1A T68I and a 11-mer synthetic peptide
identical to amino acids 276–287 of human CD150 are shown. The
peptide tyrosine residue was either phosphorylated or not (Tyr(P)281 or
Tyr281); a fluorescein group was attached to the -NH2 group of each
peptide. a, GST-WT SH2D1A (), GST-SH2D1A T53I (Œ), or GST-
SH2D1A T68I (f) binding to Tyr(P)281. b, GST-WT SH2D1A (), GST-
SH2D1A T53I (Œ), or GST-SH2D1A T68I (f) binding to Tyr281. x axes,
protein concentration (M); y axes, polarization unit (mP). c, summary
of the apparent dissociation constant (kD) of WT SH2D1A and the T53I
and T68I mutants for each peptide calculated as described under “Ex-
perimental Procedures.”
FIG. 5. Structural modeling of the interaction between the
SH2D1A T53I mutant and the CD150 Tyr281 cytoplasmic tail
peptide. The surface representations of SH2D1A T53I (upper panel)
and WT SH2D1A (lower panel) are shown. Arrows indicate the Tyr(P)
pocket in SH2D1A, position 53 in SH2D1A (violet in SH2D1A T53I),
and Thr279 and Tyr281 of the CD150 peptide. The bound peptide is
shown in a stick representation (yellow). Replacement of Thr53 by iso-
leucine severely affects the binding pocket for Thr279 (position 2) of
the CD150 peptide, severely impairing the SH2D1A/non-phosphoryl-
ated CD150 interaction.
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tutions that disrupt the Tyr(P)-binding pocket (R32Q and
C42W) or that interfere with the recognition of residues at
positions 2 (Thr) and 3 (Val) of the binding motif (T53I and
T68I, respectively) differentially compromise SH2D1A binding
to CD150-related receptors.
DISCUSSION
The SH2D1A gene encodes a single SH2 domain protein
involved in signal transduction events in T lymphocytes. The
availability of missense mutations throughout the SH2D1A
sequence provides a useful tool to dissect SH2 domain struc-
ture/function relationships. This study represents the analysis
of 10 single amino acid substitutions found in XLP patients.
Each of these mutation affects an amino acid residue that is
conserved among different species: human, rhesus monkey,
cotton-top tamarin, and mouse (Fig. 1).
A summary of the SH2D1A biochemical characterization is
shown in Table I. The missense mutations of SH2D1A are
clustered into two major groups according to their effect on
protein stability and binding to the receptors. A structural
evaluation of the mutations allows further classification (Fig.
7). The two protein groups are determined by 1) protein insta-
bility, as judged by a substantially decreased half-life (e.g.
mutants Y7C, S28R, Q99P, P101L, V102G, and X129R), or 2)
an impaired ability of binding to CD150 and CD150-related
receptors while maintaining protein stability (e.g. C42W, T53I,
and T68I). The SH2D1A R32Q mutant belongs to both groups,
as its failure to bind CD150-related receptors is accompanied
by a substantially decreased half-life.
Group 1 mutants are all in principle capable of binding to the
CD150 motif via a three-pronged interaction. The observation
that some of them (i.e. P101L and Stop129R) are capable of
binding the CD150 peptide in vitro (data not shown) while
FIG. 6. Analysis of in vivo binding of SH2D1A mutants to CD244, CD229, and CD84. In vivo interactions were examined after
cotransfection of combinations of WT SH2D1A or mutant proteins R32Q, C42W, T53I, and/or T68I (in pCMV-FLAG) with CD244, CD229, or CD84
into COS-7 cells. Combinations of cDNAs used in the transfections are indicated above panels A–D (, transfection of the indicated molecule; ,
transfection with an equal amount of empty vector). A cDNA encoding human Fyn was cotransfected as indicated (). In lanes 1 and 2 of each
panel, an equal amount of pCMV-FLAG empty vector (cmv) was used. I.P., immunoprecipitate; W.L., whole lysate. All cells were biotinylated prior
to subjection to detergent lysis. Cell lysates (1  107 cell eq) were subjected to immunoprecipitation with monoclonal antibody recognizing the
CD150-related surface receptors. Samples were analyzed by Western blotting (W.B.) with anti-phosphotyrosine antibody (-PY), horseradish
peroxidase-conjugated avidin (AV-HRP), anti-FLAG antibody, and anti-SHP-2 antibody, as indicated to the left of each panel. A, SH2D1A C42W
and T53I binding to CD244; B, SH2D1A T68I binding to CD244; C, SH2D1A R32Q, C42W, T53I, and T68I binding to CD84; D, SH2D1A R32Q,
C42W, T53I, and T68I binding to CD229.
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failing to block recruitment of SHP-2 in the COS-7 cells indi-
cates that there is a threshold level of SH2D1A in the cell below
which a propensity for XLP develops. This is consistent with
the partially defective transcription of SH2D1A in an XLP
patient who has a mutation in the 5-splice acceptor site of the
second exon (16). This XLP patient still produces 5–10% of WT
SH2D1A mRNA, which must result in a below threshold pro-
tein level (16). A limited amount of a WT protein may therefore
lead to the pathogenesis of XLP, strongly supporting the notion
that SH2D1A acts as a natural inhibitor. Group 1 mutants
contain also a protein with an amino acid substitution located
outside of the SH2 domain sequence. This mutant contains an
SH2D1A tail prolonged by an additional 11 residues because of
a mutation that transforms the stop codon to an arginine. At
first, we assumed that the SH2D1A tail might have a signifi-
cant, yet unknown, functional role. Surprisingly, pulse-chase
labeling experiments showed, however, that the additional
amino acids provide a degradation signal resulting in a short-
ened half-life of the protein. Therefore, this mutant also falls in
the first category. Its degradation could not directly involve the
ubiquitin system because it lacks a known recognition site for
the ubiquitin system. However, the additional 11-amino acid
sequence contained a PDZ recognition motif, which might serve
as a link to a protein degradation system (Scansite Software).
Group 2 mutants are stable but functionally inefficient pro-
teins due to a decreased ability to interact with CD150-related
receptors. Two mutants, C42W and T68I, do not bind to any of
the four cell-surface receptors. The C42W amino acid substitu-
tion affects interactions with the classical phosphotyrosine-
binding pocket as well as with the threonine residue at position
2 of the CD150 Tyr281 motif and consequently result in a
severe loss in binding affinity. According to the SH2D1A struc-
ture (33), Thr68 articulates interactions with the Val residue at
position3 in the CD150 Tyr281 peptide. A T68I mutation thus
disrupts the binding of CD150 Val284 to the hydrophobic cleft.
This amino acid substitution points to a critical role that Val at
position 3 plays in stabilizing SH2 domain interactions.
Of particular interest is the group 2 mutant T53I. Mutant
T53I is unusual in that it binds in a WT fashion to the phos-
phorylated tail of CD150 (kD 250 nM) and competes against
SHP-2 recruitment. However, it displayed a severely decreased
binding affinity versus the non-phosphorylated CD150 peptide
(dissociation constant of 8–9 M). Analysis of the SH2D1A
structure indicates that the isoleucine replacing Thr53 elimi-
nates the binding pocket for Thr279 of CD150 (Thr at position
2). This prevents the interaction of Thr at position 2 with
the buried water molecule and with Glu17, thereby blocking
interactions of one of the amino acids located N-terminal to
Tyr281. Whereas the SH2D1A T53I mutant still efficiently
binds to phosphorylated CD150, T53I fails to efficiently bind to
three other SH2D1A-interacting molecules, CD244, CD229,
and CD84. These results indicate the important role that motif
interactions of Tyr at position 2 play in stabilizing SH2D1A
SH2 domain binding to its receptors. Conventional SH2 do-
mains contain Ile or Leu at position D4, which is Thr53 in
SH2D1A. Replacing threonine by isoleucine in mutant T53I
may change the unique SH2 domain of SH2D1A into a more
conventional SH2 domain structure that is able to bind to a
phosphotyrosine motif only. Altogether, these data suggest
that the ability of SH2D1A to bind non-phosphorylated Tyr
peptides (probably the most striking SH2D1A feature) depends
at least partially on its peculiarity to coordinate Tyr N-termi-
nal interactions.
All the missense mutations in the SH2D1A gene investigated
in this study had fatal consequences for the XLP patients. The
clinical analysis of several members of six families affected by
SH2D1A missense mutations (Y7C, S28R, C42W, T53I, Q99P,
and V102G) shows that for a given mutant, a combination of
different phenotypes is found (Table II). In particular, we could
not find significant differences in terms of onset of the disease,
frequency of fatal infectious mononucleosis, median age of
death, the frequency of lymphoma, and the presence or absence
of EBV (Table II). Whether other elements are able to shape the
clinical phenotype remains to be investigated.
In conclusion, our results indicate a correlation between
different types of SH2D1A signal transduction abnormalities
TABLE I
Summary of SH2D1A mutant biochemical characterization
+, highly decreased half-life; , half-life similar to that of WT SH2D1A; ND, not determined; , absence of binding; , presence of binding; ,
weak binding.
SH2D1A
Y7C S28R R32Q C42W T53I T68I Q99P P101L V102G X128R
Half-life + + +    + + + +
Binding to:
CD150 ND ND     ND ND ND ND
CD244 ND ND ND    ND ND ND ND
CD229 ND ND     ND ND ND ND
CD84 ND ND     ND ND ND ND
FIG. 7. Ribbon diagram of the SH2D1A SH2 domain with the
locations of the XLP amino acid substitutions studied in this
work. A ribbon diagram of the SH2D1A SH2 domain is represented.
Lateral chains of amino acid positions where missense mutations have
been identified in XLP patients are colored accordingly to the type of
biochemical/structural alteration identified (brown, missense muta-
tions leading to protein instability with severely decreased protein
half-life; green, missense mutations leading to a disruption of the phos-
photyrosine-binding pocket; yellow, missense mutation interfering with
C-terminal motif interactions; violet, missense mutation interfering
with N-terminal motif interactions).
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(i.e. stability or binding) with the location of the amino acid
substitution. Taken together, the analysis of these selective
alterations in the SH2D1A structure indicated two distinct
mechanisms underlying the pathogenesis of XLP. First, limited
amounts of SH2D1A, attributable to protein instability, lead to
the disease. Second, the disruption of binding to the CD150-
related receptors per se leads to XLP. Because these biochem-
ical findings are not paralleled by differences in terms of XLP
disease clinical phenotypes or severity, we conclude that signal
transduction through CD150, CD229, CD244, and CD84 recep-
tors is likely redundant. Additional unidentified genetic or
environmental factors must account for the variability in XLP
disease manifestations. Moreover, these results indicate that
SH2D1A controls several distinct signal transduction path-
ways in T and NK cells.
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TABLE II
Summary of clinical data
FIM, fatal infectious mononucleosis; LPD, lymphoproliferative disorders; dysG, dysgammaglobulinemia; AA, aplastic anemia; y, years.
SH2D1A
Y7C S28R C42W T53I Q99P V102G
Affected males in the
family
3 6 5 14 17 2
Clinical phenotypes of
affected males
FIM, AA LPD, dysG FIM, dysG FIM, LPD,
dysG
FIM, LPD,
dysG
FIM
Median age of onset 8.9 y 11.18 y 8.0 y 4.5 y 7.15 y 25.6 y
Median age of
survivals
No survival 33 y,
two survivals
41 y,
one survival
21.5 y,
four survivals
35 y,
five survivals
No survival
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